Global Psoriasis Drugs Market to reach USD 26 billion by 2027. Global Psoriasis Drugs Market is valued approximately at USD 13.418 billion in 2020 and is projected to grow with a healthy growth rate of more than 9.89% over the forecast period 2021-2027. Psoriasis is a common, chronic, non-communicable skin disease, with no clear cause and cure. It affects the people of all ages, and in all countries. The changing lifestyles of people are leading to increased alcohol consumption and smoking, an unhealthy diet, and sedentary living, which makes people more prone to this condition. The immune system and genetics also play major roles in its development. The treatment of psoriasis is still based on controlling of symptoms. The key driving factors contributing to growth of psoriasis drugs market are increasing disease burden and demand for psoriasis medication in emerging economies for efficient and long-lasting effects. For instance, On 2019, the world health organization has noted that the psoriasis prevalence is on substantial rise from 2.5% in 2011 to 3.6% in 2017., considering psoriasis a serious global problem. Thus, the increasing prevalence of psoriasis and favorable government initiatives are providing boost to the market. Owing to the above-mentioned factors, the market is expected to register a high growth rate during the forecast period. Despite this, potential side-effects of most existing medication, extensive drug development and approval process and importantly, and huge cost for treatment and diagnosis. are expected restraints that could hamper the growth of the market in the long run.

North America is expected to dominate the psoriasis market during the forecast period with the highest CAGR. In North America, the United States holds the largest market share owing to the high prevalence of psoriasis, the presence of favorable government initiatives and the presence of developed healthcare infrastructure, etc.

Major market player included in this report are

Amgen Inc.
AstraZeneca
Biogen Idec
Novartis AG
Celgene Corporation
Dr. Reddy's Laboratories
Sun pharmaceutical Industries Limited
Pfizer Inc
Johnson and Johnson
Eli Lilly and Company

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Treatment Type:
Biologic Drugs
Small Molecule Systemic Drugs
Tropical Therapies
By Mechanism of action:
TNF Alpha Inhibitors
PDE4 Inhibitors
Interleukin Inhibitors
Other Mechanisms of Action
By Route of Administration:
Oral
Parenteral
Topical
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.

Target Audience of the Global Maple Water Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors